Lloyd M. Segal, MBA


Lloyd M. Segal is a member of the Board of Directors for Aktis Oncology. Lloyd is President & CEO of Repare Therapeutics (Nasdaq: RPTX), a Boston and Montreal-based, clinical-stage oncology drug developer. From 2010-2016 he was a Managing Partner at Persistence Capital Partners, a leading healthcare private equity investor, and from 2016-2020 was an entrepreneur-in-residence with Versant Ventures in San Francisco. He previously held CEO roles at Caprion Pharmaceticals (now CellCarta), which he co-founded, Advanced Bioconcept and Thallion Pharmaceuticals. After serving on multiple public boards including NYSE, NASDAQ and TSX-listed entities, in 2013, Lloyd was honored by the Financial Times as Outstanding Corporate Director of the Year. His Board service includes serving as Chairman of LMC Diabetes & Endocrinology, North America’s largest community endocrinology and diabetes practice, and Chairman of MedReleaf (TSX:LEAF), until its $2.5 billion sale to Aurora, and also as a member of the Board of GBC American Fund, a US growth-focused mutual fund. Lloyd holds a BA from Brandeis University and an MBA from Harvard Business School.